Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Eagle who wrote (58335)	4/11/2007 7:15:16 PM
From: hotlinktuna	Read Replies (2) \| Respond to of 59879

Hi Eagle! I see RNVS 4.30 close presents in NY 8:00am Eastern: RNVS 4.30 close presents tomorrow morning at 8:00am EDT in New York: Renovis to Present at the CIBC Biotechnology and Specialty Pharmaceuticals Conference Monday April 9, 8:30 am ET SOUTH SAN FRANCISCO, Calif., April 9 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS - News) today announced that Corey S. Goodman, Ph.D., President and Chief Executive Officer, will present at the CIBC Biotechnology and Specialty Pharmaceuticals Conference in New York on Thursday, April 12 at 8:00 a.m. Eastern Daylight Time. To access the live webcast, please visit Renovis' homepage, renovis.com. The above link is good for both the live and archived webcast. An archived version of the webcast will be available in the same location for ninety days following the presentation. About Renovis Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on purinergic receptors for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury. For additional information about the company, please visit www.renovis.com. -------------------------------------------------------------------------------- Source: Renovis Inc. Will be watching it for entry in the PM as it may still have more left in it imho given the upgrades and other positive news the past 2 days...tuna